NCT06147401

Brief Summary

Optimal pain control with limited muscle weakness is paramount for a swift initiation of physical therapy and ambulation. Fascia iliaca compartment block (FIC) has been recommended since it offers the best pain control with low risk of motor block. Pericapsular nerve group block (PENG) with lateral femoral cutaneous block (LFCN) has been proposed as an effective alternative to FIB that offers similar pain control with a considerably lower risk of motor block. The aim of this study is to compare the afore mentioned blocks and determine which one yielded the least degree of quadriceps femoris muscle weakness and the better pain control (the lowest NRS score with least need for opioids).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
58

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Nov 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 17, 2023

Completed
3 days until next milestone

Study Start

First participant enrolled

November 20, 2023

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 27, 2023

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2024

Completed
Last Updated

December 18, 2024

Status Verified

December 1, 2024

Enrollment Period

5 months

First QC Date

November 17, 2023

Last Update Submit

December 15, 2024

Conditions

Keywords

ERASPostoperative muscle weaknessRegional BlockPost Operative Analgesia

Outcome Measures

Primary Outcomes (3)

  • MRC at 6h

    evaluation of the degree of weakness or residual paresis of the quadriceps femoris muscle on the operative side using 'the Oxford Scale' (aka Medical Research Council Manual Muscle Testing scale or MRC scale) The MRC scale is a 0-5 scale, with zero meaning "no contraction " and five meaning "Full range of motion against gravity with full resistance".

    six hours after performing the regional anesthesia technique

  • MRC at 24h

    evaluation of the degree of weakness or residual paresis of the quadriceps femoris muscle on the operative side using 'the Oxford Scale' (aka Medical Research Council Manual Muscle Testing scale or MRC scale) The MRC scale is a 0-5 scale, with zero meaning "no contraction " and five meaning "Full range of motion against gravity with full resistance".

    24 hours after performing the regional anesthesia technique

  • MRC at 48h

    evaluation of the degree of weakness or residual paresis of the quadriceps femoris muscle on the operative side using 'the Oxford Scale' (aka Medical Research Council Manual Muscle Testing scale or MRC scale) The MRC scale is a 0-5 scale, with zero meaning "no contraction " and five meaning "Full range of motion against gravity with full resistance".

    48 hours after performing the regional anesthesia technique

Secondary Outcomes (7)

  • time to first postoperative ambulation

    From date of surgery until up to 72 hours after

  • Pain control at 6h

    six hours after performing the regional anesthesia technique

  • Pain control at 24h

    24 hours after performing the regional anesthesia technique

  • Pain control at 48h

    48 hours after performing the regional anesthesia technique

  • MME of PRN opioid total doses

    From date of surgery until up to 72 hours after

  • +2 more secondary outcomes

Other Outcomes (4)

  • Complication

    From date of surgery until up to 72 hours after

  • the degree of hip flexion

    six hours after performing the regional anesthesia technique

  • the degree of hip flexion

    24 hours after performing the regional anesthesia technique

  • +1 more other outcomes

Study Arms (2)

PENG - LFCN Block

EXPERIMENTAL

group in which PENG and LFCN Block was performed. After performing neuraxial anesthesia, the PENG associated with LFCN block will be performed. Under ultrasound guidance, 20ml and 5ml of Ropivacaine 0.5% will be administered respectively.

Procedure: PENG plus LFCN block

FIC Block

ACTIVE COMPARATOR

group in which FIC Block was performed After performing neuraxial anesthesia, FIC block will be performed. Under ultrasound guidance, 20 ml of Ropivacaine 0.5% will be administered.

Procedure: FIC Block

Interventions

The experimental arm will be subjected to a combination of peripheral blocks: the interfascial block of the PENG and the perinervous block of the LFCN The PENG block involves deposition of local anesthetic in the fascial plane between the psoas muscle and the superior pubic ramus. The LFCN block consists of applying local anesthetic near the nerve. The LFCN lies in the subcutaneous plane deep to the fascia lata below the anterior superior ischiatic spine.

Also known as: Pericapsular nerve group block and lateral femoral cutaneous nerve block, PENG and lateral femoral cutaneous nerve block
PENG - LFCN Block
FIC BlockPROCEDURE

The control arm will be subjected to an interfascial block, the fascia iliaca Compartment Block. The FICB consists in the injection of anaesthetic agents into the fascia iliaca compartment.

Also known as: Fascia Iliaca Compartment Block, FICB
FIC Block

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • elective total hip replacement surgery for non-traumatic hip disease,
  • THA (total hip arthroplasty) with lateral approach
  • age \>18 years,
  • signed consent form for spinal anesthesia and peripheral nerve block provided by the patient or legal guardian if appointed

You may not qualify if:

  • Non elective THA
  • Lack of consent to the procedure
  • Contraindications to performing neuraxial anesthesia (i.e. Signs suggestive of puncture site infection, INR \> 1.5, aPTT \> 1.5, PLT \< 40.000)
  • Documented or suspected allergy to local anesthetics

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ospedale Edoardo Bassini

Cinisello Balsamo, Milano, 20092, Italy

Location

MeSH Terms

Conditions

Pain, Postoperative

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
The anesthetist in the operating room will be the only one who knows what treatment has been administered Participant: the patient will not know the type of block he will be subjected to, because of he will already be subjected to neuraxial anesthesia. Outcomes Assessor: a clinician external to the practice will evaluate the degree of residual paralysis after anesthesia and pain control Investigator: the statistician will not know which anesthetic technique was administered to which group
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: A double-blind, randomized, controlled trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

November 17, 2023

First Posted

November 27, 2023

Study Start

November 20, 2023

Primary Completion

May 1, 2024

Study Completion

June 1, 2024

Last Updated

December 18, 2024

Record last verified: 2024-12

Locations